Evidence map›Paper›PMID 42714765›Full record

ReviewMolecular neurobiology2026

GPCR-Driven Muscarinic M1 and Histamine H1 Receptor Signaling Converging on the PI3K/Akt/mTOR Pathway: Functional Integration in Neuroinflammation and Myelin Repair in Multiple Sclerosis.

Rohit Kumar Singh, Janvi Verma, Sidharth Mehan, Divya Choudhary, Zuber Khan, Rajaram Samant, Manoj Tongra

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rohit Kumar SinghDivision of Neuroscience, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, 142001, India.
Janvi VermaDivision of Neuroscience, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, 142001, India.
Sidharth MehanDivision of Neuroscience, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, 142001, India. sidh.mehan@gmail.com.ORCID https://orcid.org/0000-0003-0034-835X
Divya ChoudharyDivision of Neuroscience, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, 142001, India.
Zuber KhanDivision of Neuroscience, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, 142001, India.
Rajaram SamantCelagenex Research, Thane, Mumbai, India.
Manoj TongraCelagenex Research, Thane, Mumbai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis is a chronic immune-mediated neurodegenerative disorder characterized by inflammation, demyelination, axonal injury, and progressive neurological disability. Although current disease-modifying therapies effectively reduce relapse frequency and peripheral immune activation, they provide limited protection against long-term neurodegeneration and remyelination failure. Emerging evidence suggests that neurotransmitter receptor-linked intracellular signaling pathways play crucial roles in regulating neuroinflammation, glial function, and neuronal survival. This review comprehensively examines the interconnected roles of the CHRM1, H1R, and the PI3K/Akt/mTOR signaling pathway in MS pathophysiology. CHRM1 and H1R both G protein-coupled receptors widely expressed in neurons, glial cells, and immune cells, modulate intracellular calcium signaling, cytokine production, blood-brain barrier integrity, and oligodendrocyte precursor cell dynamics. Dysregulated activation of these receptors contributes to persistent neuroinflammation, impaired remyelination, and synaptic dysfunction. Downstream, the PI3K/Akt/mTOR axis functions as a critical integrative hub controlling cell survival, metabolism, autophagy, and myelin protein synthesis. Balanced activation of this pathway promotes neuronal protection and oligodendrocyte maturation, whereas its chronic dysregulation exacerbates mitochondrial dysfunction, oxidative stress, and axonal degeneration. By synthesizing current experimental and mechanistic evidence, this review highlights the functional cross-talk between cholinergic and histaminergic signaling and their convergence on PI3K/Akt/mTOR-mediated cellular responses. Understanding these interconnected molecular networks provides a foundation for developing multi-target therapeutic strategies aimed at simultaneously reducing neuroinflammation, enhancing neuroprotection, and promoting remyelination in progressive MS.

Indexed as

Multiple SclerosisMyelin SheathNeuroinflammatory DiseasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptor, Muscarinic M1Receptors, G-Protein-CoupledReceptors, Histamine H1Signal TransductionTOR Serine-Threonine KinasesAnimalsHumansPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptor, Muscarinic M1Receptors, G-Protein-CoupledReceptors, Histamine H1TOR Serine-Threonine KinasesCHRM1 (Muscarinic acetylcholine receptor M1)Histamine H1 receptor (H1R)Multiple sclerosisNeuroinflammationPI3K/Akt/mTOR signaling pathwayRemyelination

Identifiers

PMID42714765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.